Dexasone
Childhood Acute Lymphoblastic Leukemia
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Tanja Andrea Gruber
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04996160CT.gov Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT05190952CT.gov Dexamethasone & Ketamine as Adjuvants to Bupivacaine for Incisional Infiltration in Pediatric Abdominal Operations | — | Completed | — | — | — |
NCT03571321CT.gov Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
NCT03817320CT.gov PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03643276CT.gov Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | — | Recruiting | — | — | — |
NCT03705507CT.gov International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia | — | Terminated | — | — | — |
NCT03467256CT.gov CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | — | Unknown | — | — | — |
NCT03020030CT.gov Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | — | Active Not Recruiting | — | — | — |
NCT03390387CT.gov Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) | — | Unknown | — | — | — |
NCT01403415CT.gov Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Show 5 more trialsShow fewer
NCT01363128CT.gov Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Completed | — | — | — |
NCT01088763CT.gov Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | — | Terminated | — | — | — |
NCT00439296CT.gov ABT-751 With Chemotherapy for Relapsed Pediatric ALL | — | Terminated | — | — | — |
NCT00061945CT.gov Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00022737CT.gov Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Tanja Andrea Gruber | P3 | BBB · 72 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
| Methotrexate | Children's Oncology Group | P3 | BBB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P3 | BBB |
| Cytarabine | Children's Oncology Group | P3 | BBB |
| Nivestim | St. Jude Children's Research Hospital | P3 | BBB |
| Mercaptopurine Anhydrous | The Children's Hospital of Zhejiang University School of Medicine | P3 | BBB |
| Pegaspargase | University of Chicago | P3 | BBB |
| Etoposide | Martin Schrappe | P3 | BBB |
+42 more in the Childhood Acute Lymphoblastic Leukemia cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Dexasone in Childhood Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/dexasone-childhood-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →